<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636244</url>
  </required_header>
  <id_info>
    <org_study_id>SHP-141-POC-0004-PTL</org_study_id>
    <nct_id>NCT02636244</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of SHAPE Gel in Alopecia Areata</brief_title>
  <official_title>A Multi-Center, Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of SHAPE Gel, a Histone Deacetylase Inhibitor, in Patients With Alopecia Areata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TetraLogic Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TetraLogic Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of SHAPE Gel applied
      topically to adult patients with alopecia areata of the scalp.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response evaluated using modified Severity of Alopecia Tool (mSALT)</measure>
    <time_frame>Every 4 weeks; up to 24 weeks</time_frame>
    <description>Severity of Alopecia Tool (SALT) estimates percent scalp hair loss and percent regrowth of hair following intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects on quality of life using Subject Assessment of Hair Loss (SAHL)</measure>
    <time_frame>Every 4 weeks; up to 24 weeks</time_frame>
    <description>The SAHL compares baseline hair volume and hair density with end of treatment hair volume and density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on quality of life using Alopecia Areata Symptom Impact Scale (AASIS)</measure>
    <time_frame>Every 4 weeks; up to 24 weeks</time_frame>
    <description>AASIS rates the severity of alopecia areata symptoms and interference of alopecia areata with daily functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on quality of life using the Skindex-16</measure>
    <time_frame>Every 4 weeks; up to 24 weeks</time_frame>
    <description>Skindex-16 assesses how often symptoms or signs of alopecia areata have been bothersome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (safety and tolerability)</measure>
    <time_frame>Every 4 weeks, up to 12 weeks</time_frame>
    <description>Evaluation of safety and tolerability will be assessed through adverse events (AEs), vital signs, physical examination, assessment of local skin changes and changes in clinical laboratory parameters</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic effect determined through assessment of lymphocyte subsets</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Measured by CD3, CD4 and CD8 lymphocytes in skin as well as by other assessments of immune modulation in the scalp</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>SHAPE Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% SHAPE Gel applied twice daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHAPE Gel</intervention_name>
    <arm_group_label>SHAPE Gel</arm_group_label>
    <other_name>SHP-141</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of scalp alopecia areata and scalp hair loss due to alopecia areata for a
             minimum of six months and a maximum of two years.

          -  Patients taking thyroid medication or hormonal therapy must be on a stable dose for 6
             months and maintain such throughout the study.

          -  Willingness to maintain same hair style, including shampoo and hair dye, throughout
             the study period.

          -  Willingness to have a small micro dot tattoo placed to allow for photographic analysis
             of treatment and application of study medication.

        Exclusion Criteria:

          -  History of systemic or cutaneous malignancy and/or lymphoproliferative disease, other
             than patients with: up to 3 basal cell carcinoma; up to three well differentiated
             cutaneous squamous cell carcinoma; and/or cervical intraepithelial neoplasm (CIN),
             treated successfully with no evidence of disease, and treated for greater than 6
             months prior to study entry.

          -  Current actinic keratosis on the scalp and/or face

          -  Nevi or cutaneous lesions thought suspicious for malignancy.

          -  History of or current gastrointestinal, pulmonary, cardiovascular, genitourinary or
             hematological disease, CNS disorders, infectious disease or coagulation disorders that
             would preclude participation in and completion of study assessments.

          -  Positive for hepatitis B surface antigen, HIV or hepatitis C.

          -  Co-existent androgenetic alopecia: in males: Norwood-Hamilton stage IV, V or VI; in
             females: Ludwig stage II or III.

          -  Unwillingness to discontinue use of non-breathable wigs, weaves or shaving of scalp
             throughout course of study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Judith Schnyder</last_name>
    <phone>610-889-9900</phone>
    <phone_ext>151</phone_ext>
    <email>jschnyder@tlog.com</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

